TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gelatin in ICU and Sepsis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients ≥ 18 years of age~* Women of child bearing potential must test negative on standard pregnancy test (urine or serum)~* Patients with body weight ≤ 140 kg~* Patients diagnosed severe sepsis / septic shock at admission on Intensive Care Unit who can be enrolled within 90 min after admission OR patients diagnosed severe sepsis / septic shock during Intensive Care Unit stay who can be enrolled within 90 min after diagnosis~* Patients where antibiotic therapy has already been started (prior to randomization)~* Patient who are fluid responsive. Fluid responsiveness is defined as increase of \> 10% in mean arterial pressure (MAP) after passive leg raising (PLR)~* Signed informed consent by patient, legal representative or authorized person or deferred consent~Exclusion Criteria:~* Administration of HES, dextrane solutions or \> 500 ml of Gelatin solutions within the 24 h prior to randomization~* Death expected within the next 48 h (moribund patients as defined by ASA ≥ class V)~* Patients for whom the need of pressure infusions are expected~* Patients with confirmed acute SARS-CoV-2 (COVID-19) infection (as available from routine medical records/ patient chart)~* Requirement for renal support (either continuous or discontinuous techniques, including intermittent haemodialysis, haemofiltration and haemodiafiltration)~* Patients receiving therapeutic heparin medication due to chronic coagulation disease / anticoagulation medication (i.e. partial thromboplastin time \> 60 sec)~* Acutely burned patients~* Contraindications according to summary of product characteristics of investigational test and reference product~* Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Gelatine (Type: EXPERIMENTAL): Balanced gelatine solution
- Electrolyte (Type: ACTIVE_COMPARATOR): Balanced electrolyte solution

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Evaluating Metabolic Mechanisms of Ertugliflozin in Diabetes & Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age \> 18 years old but \< 75 years old~* No HF hospitalization within 6 months~* Overweight or Obesity defined as BMI \> 29 but \< 42~* History of insulin resistance or T2DM and on oral diabetes agents other than SGLT2i (HgbA1c \> 5.8% and \< 10.5%)~* EF calculated based on a recent echo/cath/nuclear study at screening (pre-enrollment) \> 50%~* Stable HFpEF (HF with preserved ejection fraction) medications use of 3 months with no plans to changes or add medications for at least 12 weeks course of the study)~Exclusion Criteria:~* Acute HFpEF hospitalization within 6 months of enrollment.~* CKD stage 4 or 5 (eGFR \< 30 ml/min by CKD-EPI equation).~* Other known causes of HF including poorly controlled hypertension (SBP \>160 mm Hg) or ischemic cardiomyopathy (etc).~* Anemia (Hgb \< 11.0 mg/dL for women and \< 12.0 mg/dL for men) or severe thrombocytopenia (platelets \< 50,000 mm3)~* Anticipated changing of HF medication during anticipated study period.~* HFREF (LV EF \< 50%).~* Acute coronary syndrome, transient ischemic attack, CVA or critical limb ischemia during the last 6 months or coronary/peripheral revascularization within the last 3 months. Severe life threatening illness or live expectancy \< 6 months.~* Contraindications to MRI (metallic implants, severe claustrophobia) or treadmill exercise (limb amputation, severe osteoarthritis or equivalent functional mechanical limitation).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Ertugliflozin Treatment Arm (Type: EXPERIMENTAL): Ertugliflozin 5 mg tablet once a day for 12 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Placebo tablet once a day for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of AK120 in the Treatment of Subjects With Moderate-to-severe Asthma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~1. Male or female subjects aged ≥18 years old and ≤75 years old;~2. Asthma was diagnosed ≥ 12 months before screening, current stable treatment with medium-to-high-dose inhaled glucocorticoids plus up to two additional controllers ≥ 3 months;~3. Blood eosinophil≥ 200 cells per microliter within 6 months before screening;~4. During the screening, 40% of the predicted normal value \< pre-bronchodilator FEV1 \< 80% of the predicted normal value, within 12 months before randomization, reversible airflow restriction was recorded;~5. Asthma was inadequately controlled;~6. For women with childbearing potential, they are not pregnant or lactating, and the subjects and their partners voluntarily take effective contraceptive measures judged by the investigators during the treatment and at least 3 months after last dose.~Key Exclusion Criteria:~1. Subjects with lung diseases other than asthma, which may affect the subject's health or end point evaluation of the study;~2. Subjects had severe exacerbation events or systemic glucocorticoids usage within 1 month before randomization;~3. Respiratory tract infection and any serious infection within 1 month before randomization;~4. Subjects with parasitic infection, active tuberculosis infection, Hepatitis B, hepatitis C, human immunodeficiency virus (HIV) or syphilis positive confirmation test;~5. Known or suspected history of immunosuppression;~6. History of malignant tumors;~7. A history of smoking: those who had quit smoking for ≤ 6 months before screening, or smoking history \> 10 pack per year;~8. Previous treatment with interleukin-4 (IL-4) or interleukin-13 (IL-13) inhibitors, and inadequate washout period of other biologic therapy;~9. Allergen immunotherapy within 3 months before randomization;~10. Progressive or uncontrolled other diseases or any other conditions or abnormal laboratory tests for which the investigator assess that the subjects are not suitable to enrol in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- AK120 regimen 1 (Type: EXPERIMENTAL): None
- AK120 regimen 2 (Type: EXPERIMENTAL): None
- AK120 regimen 3 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Let It Out (LIO) and COVID19: Testing an Online Emotional Disclosure-based Intervention During the COVID19 Pandemic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* English speaking adults over the age of 18~* Able to read and write clearly in English~Exclusion Criteria:~* None

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- LIO-C (Type: EXPERIMENTAL): Participants receive LIO-C writing intervention
- Neutral writing control (Type: PLACEBO_COMPARATOR): Participants receive neutral writing control intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy male and female infants aged 9 - 12 months will be recruited from Vellore, India and Dhaka, Bangladesh.~All subjects must satisfy the following criteria at study entry:~1. Male or female infants aged 9 - 12 months whose parents or primary caretaker have given the written informed consent prior to study entry~2. Will comply with the requirements of the protocol (i.e. available for follow-up visits and specimen collection).~3. Healthy subjects as determined by:~   * Medical history~  * Physical examination~  * Clinical judgment of the investigator~Exclusion Criteria:~1. Parents or primary caregiver are unwilling or unable to give written informed consent to participate in the study~2. Ongoing serious chronic disease~3. Immunocompromising condition or therapy~4. Abdominal pain or cramps, loss of appetite, nausea, general ill-feeling or vomiting in the past 24 hours~5. Intake of any anti-diarrheal medicine in the past week~6. Acute disease one week prior to enrollment, with or without fever. Temperature ≥38ºC (oral) or axillary temperature ≥ 37.5ºC warrants deferral of the vaccination pending recovery of the subject~7. Receipt of antibiotics in the past 2 weeks~8. Receipt of live or killed enteric vaccine in the last 4 weeks~9. Diarrhea (3 or more loose stools within a 24-hour period) 6 weeks prior to enrollment~10. One or two episodes of diarrhea lasting for more than 2 weeks in the past 6 months~11. One or two episodes of abdominal pain lasting for more than 2 weeks in the past 6 months~12. Receipt of killed oral cholera vaccine~13. Have previously received a dose of a measles-containing vaccine (MCV)~14. Have previously presented with a disease potentially related to measles~15. Receipt of blood, blood products or a parenteral immunoglobulin preparation in the previous 3 months~16. History of anaphylaxis, any serious vaccine reaction, allergy to eggs, egg products or to any measles vaccine component~17. any condition which in the opinion of the investigator, might interfere with the evaluation of the study objectives

- Gender: ALL
- Minimum Age: 9 Months
- Maximum Age: 12 Months
- Healthy Volunteers: t

Study Arms:
- Vaccine (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: regulatory/approval
Please assess the completion status of the following clinical trial:

Trial Title: Anesthesic Propofol and Remifentanil Requirements in Obese Patients

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~- Patients scheduled for a bariatric coelioscopic surgical procedure (obese patients) or for an upper abdominal laparoscopic procedure (lean patients)~Exclusion Criteria:~* age lower than 18 years,~* pregnant woman,~* presence of a central neurological disorder or a lesion cerebral, of a severe respiratory or hepatic insufficiency,~* allergy to propofol, or to soja or to peanuts, or to sufentanil, or to remifentanil, or to morphine, or to a muscle myorelaxant, or to an excipient,~* hypersensibility to sufentanil, or to remifentanil or to another derivate of fentanyl,~* allergy to latex,~* presence of a symptomatic gastroesophageal reflux,~* patients receiving a psychotropic treatment or a agonist-antagonist opiate,~* presence of predictive signs of difficult mask ventilation of difficult intubation (else than obesity)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): obese patients
- 2 (Type: ACTIVE_COMPARATOR): lean patients

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy and Safety Study to Compare Fentanyl Ionsys and Routine Care With Intravenous (IV) Morphine Patient-controlled Analgesia (PCA) in Participants Who Have Undergone Elective Major Abdominal or Orthopedic Surgery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~* Participants, after an elective major abdominal or orthopedic (pertaining to bones) surgery~* Expected to have acute (a quick and severe form of illness in its early stage) moderate (medium level of seriousness) to severe (very serious) post-operative pain requiring parenteral (administration by injection) opioids (morphine like medication) for at least 24 hours after surgery~* Participants who have undergone General anesthesia (loss of sensation or feeling), spinal anesthesia of less than or equal to 4 hours duration or epidural (outside the spinal cord) anesthesia~* Participants with respiratory rate 10 to 24 breaths per minute~* Participants with a pain score less than or equal to 4 out of 10 on a Numerical Rating Scale (NRS), after titration to comfort with intravenous (IV) morphine Exclusion Criteria~* Surgery secondary to malignancy (cancer or other progressively enlarging and spreading tumor) or trauma (injury)~* History of psychological opioid dependence and/or known or suspected to be opioid dependent~* Severe chronic (lasting a long time) obstructive respiratory symptoms susceptibility to respiratory depression, moderate to severe renal (having to do with the kidney) dysfunction~* Peri-operative administration of opioids other than morphine, fentanyl, sufentanil, alfentanil or remifentanil~* Require high doses of opioids to control their pain (more than 40 milligram morphine IV) during titration to comfort, or more than 6 hours have elapsed since the participant arrived in the recovery room or Monoamine oxidase inhibitors (MAOI) within 14 days pre-study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Fentanyl IONSYS (Type: EXPERIMENTAL): Participants will receive 40 microgram (mcg) of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
- Morphine IV PCA (Type: ACTIVE_COMPARATOR): Morphine sulphate solution will be administered intravenously (directly into the vein, IV) by a patient-controlled analgesia (PCA) pump using set bolus (a large amount) doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Methylprednisolone With or Without Doxorubicin in Treating Patients With Metastatic Prostate Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS: Histologically proven, symptomatic prostate cancer Appearance or aggravation of clinical symptoms with progression of disease Bone pain OR Urethral compression OR 20% decrease in performance status Metastatic disease Local-regional or distant secondary tumors Documented radiologically or scintigraphically Hormone-refractory as defined by progression while on hormone treatment (simple castration or complete androgen blockage) Progressive disease No urethral or cervical stenosis Increase of greater than 25% prostatic volume on endorectal echography No documentation by PSA increase or imagery only Hormone castration verified by testosterone less than 0.5 ng/mL No history of CNS metastases~PATIENT CHARACTERISTICS: Age: Over 18 Performance status: Karnofsky 60-100% Life expectancy: No specified Hematopoietic: Neutrophil count greater than 1500/mm3 Platelet count greater than 100,000/mm3 Hemoglobin greater than 9 g/dL Hepatic: Bilirubin less than 1.5 times normal Renal: Creatinine less than 1.6 mg/dL Cardiovascular: Ventricular ejection fraction at least 50% Other: No contraindication to anthracycline treatment No prior primary cancer except basal cell skin cancer~PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: No prior chemotherapy Arm I: No concurrent chemotherapy Endocrine therapy: At least 1 month since prior hormone therapy, including estramustine, except LHRH agonists, which continue Arm I: No concurrent estramustine Radiotherapy: At least 3 months since prior strontium 89 No concurrent strontium Surgery: See Disease Characteristics

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 120 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: A Pilot Study Investigating the Effects of Acetyl-L-Carnitine and Vincristine-Induced Neuropathy in Pediatric Patients With ALL

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet the following inclusion criteria.~  * The subject must have a confirmed diagnosis of acute lymphoblastic leukemia within 1 week of starting therapy~ * Currently being treated on a standard ALL induction regimen~ * Subjects must be greater than or equal to 5 and less than 18 years old~ * Signed informed consent~Exclusion Criteria:~* Subjects will be excluded for the following:~  * Preexisting neurologic disease, including grade II, III, or IV neurological status by NCI Common Toxicity Criteria v3.0 on clinical exam~ * History of hypersensitivity to vincristine~ * History of hypersensitivity to Acetyl-L-carnitine~ * Previous use of Acetyl-L-carnitine~ * Concurrent anti-convulsant use~ * Concurrent Gabapentin use~ * Concurrent Glutamine use~ * Liver Function: Total bilirubin greater than 1.3 mg/dL and serum glutamic-pyruvic transaminase (SGPT) (ALT) greater than 5 x upper limit of normal for age and serum albumin less than 2 g/dL~ * Patients who are pregnant

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Acetyl-L-Carnitine only (Type: EXPERIMENTAL): The first 15 subjects participating in this study will receive Acetyl-L-Carnitine and pharmacokinetic testing will be done.
- Acetyl-L-Carnitine or Placebo (Type: EXPERIMENTAL): Subjects 16-30 will be randomized to receive drug or placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Systemic Therapy With or Without Upfront Surgery in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Newly diagnosed primary distant metastatic breast cancer (M1)~* Anticipated survival of at least 6 months~* Histologically proven breast cancer~* Hormonal and HER2Neu status should be known~* T1-T3, resectable T4 status, N0-N3~* Performance status of the patient should allow surgery / systemic therapy~* Co-morbidity of the patient should allow surgery / systemic therapy~* Age \> 18 years~* Written informed consent~Exclusion Criteria:~* Primary invasive breast cancer in medical history~* Other malignancy within the last 10 years, besides basal cell carcinoma of the skin or early stage cervical cancer~* Surgical treatment / radiotherapy of this breast tumor before randomization~* Irresectable T4 breast tumor~* Synchronous bilateral breast cancer

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Upfront surgery (Type: EXPERIMENTAL): Upfront surgery followed by systemic treatment
- Systemic therapy (Type: OTHER): Systemic therapy possibly followed by local treatment of the breast tumor

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Building Physician Resiliency Through CREATION Health: A Research Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Physician employed by Centura Health or credentialed physician with privileges at Centura Health~* Adult ≥ 18 years old~* English language proficiency~* Able to provide informed consent~* Resides in the Denver, Colorado area~* Willing to commit to the timeline of the study~Exclusion Criteria:~* Plans to reside outside of the Denver, Colorado area within the 8 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Behavioral Intervention (Type: EXPERIMENTAL): The study subjects will be recruited for approximately six weeks prior to the projected start date. The participants will attend the two-day weekend retreat. Follow-up assessments will be administered three months and six months after the retreat. The investigators will analyze the data and complete the study one month after the final assessment is administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues